Abstract
Objective Variants in the superoxide dismutase (SOD1) gene are among the most common genetic causes of amyotrophic lateral sclerosis. Reflecting the wide spectrum of putatively deleterious variants that have been reported to date, it has become clear that SOD1-linked ALS presents a highly variable age at symptom onset and disease duration.
Methods Here we describe an open access web-tool for comparative phenotype analysis in ALS: https://sod1-als-browser.rosalind.kcl.ac.uk/. The tool contains a built-in dataset of clinical information from 1,383 people with ALS harbouring a SOD1 variant resulting in one of 162 unique amino acid sequence alterations, and from a non-SOD1 comparator ALS cohort of 13,469 individuals. We present two examples of analyses possible with this tool, testing how the ALS phenotype relates to SOD1 variants which alter amino acid residue hydrophobicity, and distinct variants at the 94th residue of SOD1 which has six variants sampled at the same position.
Results and conclusions The tool provides immediate access to the datasets and enables bespoke analysis of phenotypic trends associated with different gene variants, including the option for users to upload their own datasets for integration with the server data. The tool can be used to study SOD1-ALS as well as an analytical framework to study the differences between other user-uploaded ALS groups and our large reference database of SOD1 and non-SOD1 ALS. The tool is designed to be useful for clinicians and researchers, including those without programming expertise, and is highly flexible in the analyses that can be conducted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AAK is funded by ALS Association Milton Safenowitz Research Fellowship, The Motor Neurone Disease Association (MNDA) Fellowship (Al Khleifat/Oct21/975 799), The Darby Rimmer Foundation, and The NIHR Maudsley Biomedical Research Centre. This project was also funded by the MND Association and the Wellcome Trust. This is an EU Joint Programme Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organisations under the aegis of JPND http://www.neurodegenerationresearch.eu/ [United Kingdom, Medical Research Council (MR/L501529/1 and MR/R024804/1) and Economic and Social Research Council (ES/L008238/1)]. AAC is a NIHR Senior Investigator. AAC receives salary support from the National Institute for Health Research (NIHR) Dementia Biomedical Research Unit at South London and Maudsley NHS Foundation Trust and Kings College London. The work leading up to this publication was funded by the European Communitys Health Seventh Framework Program (FP7/2007 2013; grant agreement number 259867) and Horizon 2020 Program (H2020 PHC 2014 two stage; grant agreement number 633413). This project has received funding from the European Research Council (ERC) under the European Unions Horizon 2020 Research and Innovation Programme (grant agreement no. 772376 EScORIAL. This project is also supported by funding from Avexis/Novartis and the United Kingdom Dementia Research Institute, and represents independent research part funded by the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and Kings College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, Kings College London, or the Department of Health and Social Care. A.I. is funded by South London and Maudsley NHS Foundation Trust, MND Scotland, Motor Neurone Disease Association, National Institute for Health and Care Research, Spastic Paraplegia Foundation, Rosetrees Trust, Darby Rimmer MND Foundation, the Medical Research Council (UKRI) and Alzheimers Research UK. M.K. is supported by Darby Rimmer MND Foundation and Spastic Paraplegia Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
